Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Solid State of Tulobuterol : Characterization, Dissolution, Transformation

  • Received : 2011.11.11
  • Accepted : 2011.12.19
  • Published : 2011.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this work was to investigate the existence of new crystal forms of tulobuterol which is used to prevent morning asthma attacks by ${\beta}_2$ agonist and the transformation of crystal forms. Three crystal forms of tulobuterol have been isolated by recrystallization and Form 2 was transformed to Form 4 at 52% RH and 95% RH and these four crystal forms are characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) and thermogravimetric analysis (TG). The DSC and PXRD patterns of four crystal forms of tulobuterol were different respectively. The dissolution patterns of these three crystal forms of tulobuterol were studied and they showed significant differences in the dissolution rate. After storage of 2 months at 0% RH (silica gel, $20^{\circ}C$), 52% RH (saturated solution of $Na_2Cr_2O_7{\cdot}2H_2O/20^{\circ}C$) and 95% RH (saturated solution of $Na_2HPO_4/20^{\circ}C$), Form 1 and Form 3 were not transformed. But Form 2 was transformed to Form 4 at 52% RH and 95% RH.

Keywords

References

  1. Bachet, B., 1997. X-ray characterization of the triclinic polymorph of carbamazepine. J. Pharm. Sci. 86, 1062-1065. https://doi.org/10.1021/js960338k
  2. Caira, M.R., Bourne, S.A., and Oliver, C.L., 2004. Thermal and structural characterization of two polymorphs of the bron-chodilator tulobuterol. J. Thermal. Anal. Cal., 77, 597-605. https://doi.org/10.1023/B:JTAN.0000038997.18925.b3
  3. Campeta, A.M., Chekal, B.P., Abramov, Y.A., Meenan, P.A., Henson, M.J., Shi, B., Singer, R.A., Horspool, K.R., 2010. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. J. Pharm. Sci., 99, 3874-3886.
  4. Giron, D., 1995. Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates. Thermochim. Acta, 248, 1-59. https://doi.org/10.1016/0040-6031(94)01953-E
  5. Haleblian, J.K., McCrone, W.C., 1969. Pharmaceutical applications of polymorphism. J. Pharm. Sci., 58, 911-929. https://doi.org/10.1002/jps.2600580802
  6. Haleblian, J.K., 1975. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci., 64, 1269-1288. https://doi.org/10.1002/jps.2600640805
  7. Hüttenrauch, R., 2008. Fundamentals of pharmaceutics. Acta Pharm. Technol., 34, 1-10.
  8. Lee, E.A., Sohn, Y.T., 2008. Crystal forms of a capsaicin derivative analgesic DA-5018. J. Therm. Anal. Cal., 93, 871-874. https://doi.org/10.1007/s10973-008-9076-1
  9. Opalchenova, G. and Kalinkova, G.N., 1997. Evaluation of a new polymorph azlocillin sodium by its antibacterial activity. Int. J. Pharm., 153, 263-265. https://doi.org/10.1016/S0378-5173(97)00087-2
  10. Sohn, Y.T., 2007. Crystal forms of an angiotensin II receptor antagonist BR-A657. J. Therm. Anal. Cal., 89, 799-802. https://doi.org/10.1007/s10973-005-7307-2
  11. Song, H.O. and Sohn, Y.T., 2010. Crystal forms of SK-3530. Arch. Pharm. Res., 12, 2033-2036.
  12. Yamamura, S., Momose, Y., 2001. Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data. Int. J. Pharm., 212, 203-212. https://doi.org/10.1016/S0378-5173(00)00605-0